March 16, 2023
Erica Sparkenbaugh, PhD was awarded a one-year Stage 1 SBIR grant from NHLBI (HL169107-01) titled Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease. She is a subcontract on the grant with Chris Dockendorff at Function Therapeutics as PI.
March 14, 2023
Yasmina Abajas’, MD paper ‘Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children’s Hospital Acquired Thrombosis (CHAT) Consortium’ was published in the Research and Practice in Thrombosis and Haemostasis journal. Click here to read the paper.
February 23, 2023
The results of 2 phase 3 trials of AAV-mediated gene therapy for hemophilia A and hemophilia B were published back-to-back in the New England Journal of Medicine on February 23, 2023. Dr. Nigel Key was a collaborator and co-author on both studies, each of which included patients from UNC. The hemophilia A study (Biomarin Pharmacuticals) …
February 23, 2023
Sickle cell disease carries a significant risk of venous thrombosis, yet evidence suggests that anti-coagulant therapy increases the risk of bleeding in individuals with SCD. Coagulation FXII, which contributes to thrombosis but not hemostasis, is an appealing target for treating thrombosis without carrying a bleeding risk. Work led by Erica Sparkenbaugh and Rafal Pawlinski demonstrates …
February 22, 2023
Dr. Callie Berkowitz, a second year hematology fellow, has been selected for the Promoting XXcellence in Women’s Health: Optimal Management of Women and Girls with Bleeding Disorders special research award from the Foundation for Women and Girls with Blood Disorders. Her project will explore hemostatic outcomes and patients needs in women with bleeding of unknown …
February 1, 2023
Click here to read the February 2023 Newsletter
January 31, 2023
Antoniak Lab published a study investigating the role of thrombin-PAR1 signaling in chemotherapy induced heart failure. UNC Blood Research Center researchers Drs Grover, Bharathi, Mackman and Antoniak in collaboration with Drs. Posma, Griffin and Palumbo published in Blood Advances “Thrombin mediated activation of PAR1 enhances doxorubicin induced cardiac injury in mice”. Dr. Antoniak was the …
January 31, 2023
The contact pathway of coagulation has been implicated in the pathogenesis of venous thrombosis. Relatively little, however, is known about the the role of C1 inhibitor, the major negative regulator of this pathway, in venous thrombosis. Work led by Steven Grover and Nigel Mackman revealed that C1 inhibitor deficiency, resulting in the genetic disorder Hereditary …
January 31, 2023
Work led by postdoctoral fellow Jun Wan, PhD under the supervision of Steven Grover, PhD and Nigel Mackman, PhD establishing a novel mouse whole blood thrombin generation assay has been published in the Journal Blood Advances. In this work the authors found that the novel mouse whole blood assay provided increased sensitivity to amplifying coagulation …
January 31, 2023
Congratulations to Research Assistant Professor Steven Grover, PhD who received a 2023 UNC Junior Faculty Development Award to support his work studying “The role of endogenous C1 inhibitor as a negative regulator of coagulation in the general population”. This highly competitive award is supported by the UNC Office of the Provost with funds provided by IBM and R.J. …
January 31, 2023
Rafal Pawlinski, PhD and Jian Liu, PhD were published in the Proceedings of the National Academy of Sciences (PNAS) Journal for their paper, “Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis”. Click here to read the paper.
January 26, 2023
Stephanie Reitsma’s proposal titled “Phenotypic modifiers in people with low factor XI” was awarded the American Heart Association (AHA) postdoctoral fellowship award. She will use a multidisciplinary approach to determine bleeding risk determinants in FXI deficiency. This project will be guided by her co-mentors Drs. Alisa Wolberg and Karin Leiderman for the duration of 2 …